KarenSSlobodMD
Pediatric Infectious Disease • Memphis, TNAssociate Professor, Pediatrics, University of Tennessee Health Science Center College of Medicine
Are you Dr. Slobod?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 22 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
St. Jude Children's Research Hospital
332 N Lauderdale St., Ms 0515
Memphis, TN 38105Phone+1 901-495-3006Fax+1 901-495-3842
Summary
- Dr. Karen Slobod, MD is a pediatric infectious disease specialist in Memphis, Tennessee. She is currently licensed to practice medicine in Tennessee. She is an Associate Professor at University of Tennessee Health Science Center College of Medicine.
Education & Training
University of TennesseeFellowship, Pediatric Infectious Diseases, 1989 - 1992
Montreal Children's HospitalPediatrics, 1986 - 1989
McGill University Faculty of MedicineClass of 1986
Certifications & Licensure
TN State Medical License 1993 - 2025
Clinical Trials
- Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS Start of enrollment: 1996 Oct 01
- Safety of the EnvPro HIV Vaccine in Healthy Volunteers Start of enrollment: 2003 Aug 01
Publications & Presentations
PubMed
- 7 citationsHumoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.Jaya Goswami, Abdullah H Baqui, Pablo A Doreski, Gonzalo Perez Marc, Gilberto Jimenez
The Journal of Infectious Diseases. 2024-11-15 - 2 citationsSafety and durability of mRNA-1273-induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial.Amparo L Figueroa, Kashif Ali, Gary Berman, Honghong Zhou, Weiping Deng
Eclinicalmedicine. 2024-08-01 - 2 citationsInterim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.Avika Dixit, Richard Bennett, Kashif Ali, Carl Griffin, Robert A Clifford
The Lancet. Infectious Diseases. 2024-07-01
Press Mentions
GSK Hands CureVac $294M to Form mRNA Infectious Disease PactJuly 20th, 2020
Grant Support
- Clinical And Primate Paramyxovirus Vaccine EvaluationNational Institute Of Allergy And Infectious Diseases2004–2008
- Recombinant Sendai Virus As A Novel HIV Vaccine VectorNational Institute Of Allergy And Infectious Diseases2003–2004
- Clinical Evaluation Of A Multi-Envelope AIDS VaccineNational Institute Of Allergy And Infectious Diseases1999–2002
- Treatment Of EBV Lymphoma By Induction Of Episomal LossNational Cancer Institute1997
